For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.co.jp/

The transfer of all commercial rights for Panaldine®

Tokyo, April 2, 2007 - DAIICHI SANKYO COMPANY, LIMITED and Sanofi-aventis announced today the transfer of all commercial rights for Panaldine(R) (ticlopidine hydrochloride ) in Japan from DAIICHI SANKYO to Sanofi-aventis. The transfer will be implemented in conformity with local regulatory requirements and such transfer is expected to occur on October 1, 2007. Given their long-standing relationship, both parties agreed to collaborate in the future in the areas of manufacturing and distribution in Japan.